Cargando…

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)

OBJECTIVES: To compare the completeness and agreement of prostate cancer data recorded by the National Cancer Registration and Analysis Service (NCRAS) with research-level data specifically abstracted from medical records from the Cluster randomised triAl of prostate specific antigen (PSA) testing f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merriel, Samuel William David, Turner, Emma L, Walsh, Eleanor, Young, Grace J, Metcalfe, Chris, Hounsome, Luke, Tudge, Isobel, Donovan, Jenny, Hamdy, Freddie, Neal, David, Martin, Richard M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695381/ https://www.ncbi.nlm.nih.gov/pubmed/29138196 http://dx.doi.org/10.1136/bmjopen-2017-015994

Ejemplares similares

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C, et al.
Publicado: (2016)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C., et al.
Publicado: (2023)

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
por: Williams, Naomi J, et al.
Publicado: (2015)

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Turner, E L, et al.
Publicado: (2014)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
por: Gilbert, Rebecca, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
por: Keeney, Edna, et al.
Publicado: (2022)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients
por: Merriel, Samuel W. D., et al.
Publicado: (2022)

Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study
por: Horwood, Jeremy P, et al.
Publicado: (2014)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

A model of the natural history of screen-detected prostate cancer
por: Metcalfe, C, et al.
Publicado: (2006)

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
por: Pashayan, N, et al.
Publicado: (2009)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
por: Harrison, Sean, et al.
Publicado: (2020)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data
por: Merriel, Samuel W D, et al.
Publicado: (2018)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Novel biomarkers for the detection of prostate cancer
por: Jakobsen, Niels Asger, et al.
Publicado: (2016)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Prostate Cancer in Primary Care
por: Merriel, Samuel W. D., et al.
Publicado: (2018)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022)

PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium
por: Song, Zi-Jian, et al.
Publicado: (2020)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2022)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8t28nb13ihctjiua6lr4i5gs5l